Related Experiment Video
Updated: Sep 11, 2025
The Establishment and Utilization of Patient Derived Xenograft Models of Central Nervous System Metastasis
Published on: May 7, 2021
Real-world experience outcome in patients with central nervous system metastases: information on 2,226 patients
Oscar Arrieta1, Alexandra Díaz-Alba2, Sergio Moreno-Jiménez3
1Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.
Purpose:
Most data regarding Central nervous system (CNS) metastases are derived from non-Hispanic populations enrolled in clinical trials. This study aims to characterize the primary tumors, initial treatments, and outcomes in a Hispanic/Latino real-world population with CNS metastases.
Methods:
A retrospective analysis of a multicenter cohort of patients with CNS metastases treated from 2010 to 2024.
Results:
From 2,261 patients with CNS metastases, 84% had brain metastases and 16% had neoplastic meningitis. The most common primary tumors were breast (40%), lung (27%), genitourinary (11%), gynecologic (6%), and melanoma (4%). Whole-brain radiotherapy and systemic therapy were initially prescribed in 84% and 55% of cases, respectively. The median overall survival was 9.8 months (95% CI, 8.9 - 10.7). Variables associated with outcomes included location of the primary tumor, molecular subtype, type of CNS metastases (brain metastases vs. neoplastic meningitis), and access to targeted therapies.
Conclusion:
In a real-world cohort of Hispanic/Latino patients with CNS metastases, survival has remained poor over the past 15 years. This highlights the need for interventions and research to improve outcomes.
